Showing results (121-130 of 245) with videos related to
Sort By:
Pageof 25
Scientific Reports|January 15, 2021
Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular diseaseHirotaka Saito, Kenichi Tanaka, Tsuyoshi Iwasaki, et al.Clinical and Experimental Nephrology|January 7, 2021
Association between serum potassium levels and adverse outcomes in chronic kidney disease: the Fukushima CKD cohort studyKenichi Tanaka, Hirotaka Saito, Tsuyoshi Iwasaki, et al.Internal Medicine (Tokyo, Japan)|November 22, 2021
Association between Serum Inorganic Phosphorus Levels and Adverse Outcomes in Chronic Kidney Disease: The Fukushima CKD Cohort StudyAkira Oda, Kenichi Tanaka, Hirotaka Saito, et al.Cardiovascular Diabetology|June 17, 2020
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapyMasato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 21, 2022
Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trialShinya Fujiki, Atsushi Tanaka, Takumi Imai, et al.International Journal of Environmental Research and Public Health|January 8, 2023
Longitudinal Trends in Blood Pressure Associated with The Changes in Living Environment Caused by the Great East Japan Earthquake: The Fukushima Health Management SurveySatomi Ikeda, Ai Ikeda, Tetsuya Ohira, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|May 24, 2024
Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trialAtsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, et al.Journal of Atherosclerosis and Thrombosis|December 21, 2020
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin TherapyMasato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, et al.Frontiers in Cardiovascular Medicine|November 22, 2018
Activation of Toll-Like Receptor 9 Impairs Blood Flow Recovery After Hind-Limb IschemiaSachiko Nishimoto, Kunduziayi Aini, Daiju Fukuda, et al.International Journal of Environmental Research and Public Health|May 14, 2022
The Associations between Evacuation Status and Lifestyle-Related Diseases in Fukushima after the Great East Japan Earthquake: The Fukushima Health Management SurveyZhichao Sun, Hironori Imano, Eri Eguchi, et al.Pageof 25